All seven independent directors of 23andMe resigned this week, citing disagreements with CEO Anne Wojcicki's plan to take the company private. The directors' resignation letter mentioned the lack of a 'fully financed, fully diligenced, actionable proposal' that benefited non-affiliated shareholders. Wojcicki, who holds 49% of the voting power, proposed to buy all outstanding shares at $0.40 each, but the board found the offer insufficient. Wojcicki expressed surprise and disappointment but reiterated her belief that privatization would benefit the company long-term. The genetic testing company, which went public in 2021 with a $3.5 billion valuation, has struggled financially, with shares plummeting over 95% since then. The company now faces the challenge of appointing new independent directors while dealing with its declining market position and financial struggles.